Kornimate/medical-research-clean huggingface dataset:
a study of bms-582949 in patients with moderate to severe plaque psoriasis

Conditions: Psoriasis

Summary: the purpose of this clinical research study is to learn if bms-582949 alone is an effective treatment for moderate to severe psoriasis. the safety of the drug and the effectiveness of each dose will also be studied.


Eligibility criteria:
inclusion criteria: * males and females (not nursing or not pregnant) * 18-75 years of age * diagnosis of moderate to severe psoriasis for at least six months at the time of screening * subjects will require wash-out of certain therapies for the treatment of psoriasis but will be allowed to continue on certain topical therapies
genotypic resistance guided therapy in helicobacter pylori eradication

Conditions: Self Efficacy

Summary: we aimed to compare the efficacy of genotypic resistance guided sequential therapy vs. empiric therapy in the third line therapy. factors affecting the eradication rates, including the antibiotic resistance, cyp2c19 polymorphism, caga and vaca status will also be assessed.

the primary aim of this study is to compare the regimens selected using either one of the method (1) genotypic resistance guided versus (2) medication history guided therapy. (rather than to compare the efficacy of any drugs).

Eligibility criteria:
inclusion criteria: * patients aged greater than 20 years who have persistent h. pylori infection after at least two treatments and are willing to receive third line rescue regimens are considered eligible for enrollment. exclusion criteria: * patients will be excluded from the study if any one of the following criteria is present: (1) children and teenagers aged less than 20 years, (2) history of gastrectomy, (3)gastric malignancy, including adenocarcinoma and lymphoma, (4) previous allergic reaction to antibiotics (amoxicillin, klaricid, cravit) and prompt pump inhibitors (esomeprazole), (5)contraindication to treatment drugs, (6) pregnant or lactating women, (7) severe concurrent disease.

Keywords: genotypic resistance guided therapy
intermittent normoxia reduces myocardial reperfusion injury

Conditions: Hyperoxia

Summary: this study aims to determine the effect of intermittent normoxic cardiopulmonary bypass (cpb) on inflammatory response, oxidative stress and myocardial reperfusion injury in adult patients undergoing valve replacement. the investigators hypothesized that nuclear factor kappa b (nfkb) was involved in regulating gene expression of myocardial inflammatory factor.

methods:patients meeting the requirement will be randomized into 2 groups: the control group received hyperoxic reperfusion (pao2 180-250 mmhg) throughout cpb as routine; the treatment group underwent 3 cycles of 5/5 min normal/high oxygenation (pao2 80-150/180-250 mmhg) during cardioplegia arrest, and maintained the same hyperoxia as the control group in the rest time of cpb. the clinical data of inotropes requirement, drainage, ventilation and intensive care time will be recorded. venous blood samples will be taken perioperatively for detecting concentration of troponin i (ctni), tumor necrosis factor-α , interleukin-6, 10, and malondialdehyde (mda). atrial biopsies will be removed before cardioplegia arrest and 30min after aortic de-clamping to determine the extent of neutrophil infiltration (myeloperoxidase activity), nfkb binding dna activity, and gene expression of inflammatory factors (tnf-α, il-6, 10). statistical analysis:a sample size of at least 32 patients in each group was needed to have a power of 90%, significance at the two-side 5% level, on the basis that a sd of 0.2 ng/ml and a difference in peak serum ctni release of about 0.15 ng/ml between control and conditioned patients was determined. expected results: the treatment group will have significantly lower release of ctni, inflammatory factors, and mda during cpb and afterwards. intermittent normoxia may be related to less myocardial inflammation characterized by decreased myeloperoxidase activity, gene expression of inflammatory factors, the later may result from reduced activity of nfkb binding to dna after reperfusion.

Eligibility criteria:
inclusion criteria: * rheumatic heart valve disease requiring selective aortic or double valve(aortic and mitral valve) replacement exclusion criteria: * infective endocarditis congenital valve disease previous cardiac surgery complicated with diabetes, coronary artery disease, hypertension or peripheral vascular disease. receiving aspirin, corticosteroids, angiotensin-converting enzyme inhibitors or statin perioperatively

Keywords: cardiopulmonary bypass
polycythemia, proteins and erythropoiesis

Conditions: Erythropoiesis

Summary: erythropoiesis encompasses all the stages and mechanisms involved in the production of red blood cells, or erythrocytes, under the control of a large number of regulatory agents, most often proteins. among these proteins, erythropoietin and interleukin-3 play a major role. similarly, proteins involved in iron metabolism (erythroferrone, hepcidin, ferroportin, transferrin, ferritin) influence erythrocyte production more or less directly. the regulation of erythropoiesis is a fine, complex mechanism involving a large number of players, not only through the stimulation of hypoxia pathways to control erythropoietin synthesis, but also through the availability of iron, an essential element for erythropoiesis. excessive erythrocyte production can lead to polycythemia, the causes of which are varied, primary or secondary, acquired or constitutional. the aim of this work is the descriptive study (quantitative and/or qualitative) of the various proteins involved in the regulation of erythropoiesis in patients with polycythemia. these proteins will be measured in the plasma of patients obtained after blood sampling or bloodletting (bloodletting being the most common treatment for polyglobulic patients) and will be compared with the proteins of patients without polycythemia.


Eligibility criteria:
inclusion criteria: - persons who have given their non-opposition patients with polycythemia: * haemoglobin value \> 16 g/dl female or \> 16.5 g/dl male * with a well-identified cause: either primary (polycythemia vaquez, erythropoietin receptor or lnk/sh2b3 mutation...) or secondary \[cardio-respiratory pathologies, renal pathologies (post-transplant, polycystic kidney disease), metabolic pathologies, tumour (leiomyoma, pheochromocytoma...), constitutional mutations (hyperaffine haemoglobins, hif2/epas1, phd/egln1, vhl, ...) patients control: - persons with a similar pathology to that of polycythemia patients, essentialy secondary, but without polycythemia, i.e. with a haemoglobin value of \< 16 g/dl for women and \< 16.5 g/dl for men exclusion criteria: * person subject to a measure of legal protection (guardianship, tutorship) * person subject to a court order * pregnant, parturient or nursing woman * incapable of expressing consent * minor
a clinical study of mil62 in systemic lupus erythematosus

Conditions: Systemic Lupus Erythematosus

Summary: this study will evaluate the efficacy, safety, pharmacokinetics(pk) 、pharmacodynamics(pd) and ada of mil62 compared with placebo in participants with systemic lupus erythematosus.


Eligibility criteria:
inclusion criteria: 1. age 18-80 ; 2. diagnosis of systemic lupus erythematosus according to european league against rheumatism/american college of rheumatology (eular/acr) sle classification criteria ; 3. positive antinuclear antibodies (ana) ≥ 1:80 at screening or positive anti- dsdna ; 4. low c3 and/or low c4 complement at screening ; 5. high disease activity at screening ; 6. on a stable sle treatment regimen for at least 30 days prior to the first administration； 7. able and willing to provide written informed consent and to comply with the study protocol. exclusion criteria: 1. unsufficient organ function; 2. have received treatment with b cell targeted therapy within 9 months prior to the first administration; 3. subjects with cd4+ t lymphocyte count \< 200 cells/μl; 4. receipt of any of the following prior to the first administration: cyclophosphamide,calcineurin inhibitor, blood transfusion ; 5. received tnf inhibitor, beliumumab, and tetasercept within 3 months prior to the first administration; interleukin monoclonal antibody, jak inhibitor, btk inhibitor within 2 months prior to the first administration; 6. received live or attenuated vaccination within 28 days prior to the first administration; 7. participated in other clinical trials within 28 days prior to the first administration; 8. concomitant with other serious diseases； 9. infection with human immunodeficiency virus (hiv), hepatitis b or hepatitis c; 10. subjects with known history of severe allergic reactions to humanized monoclonal antibodies，mil62； 11. breastfeeding or pregnant women; 12. childbearing potential and unwillingness or impossibility to comply with a scientifically acceptable birth-control method; 13. other conditions unsuitable for participation in this study determined by the investigator.
application of transversus abdominus plain block, local subcutaneous injection and iv nalbuphine

Conditions: Post Operative Pain; Cesarean Section Pain

Summary: approximately 1 in 5 women who undergo cs will experience severe acute postoperative pain. the severity of pain in the acute postoperative period is a significant predictor for the development of chronic pain, which occurs in 9.2%-18% of women who undergo cs. furthermore, severe acute post-cesarean pain triples a woman's risk of developing postpartum depression and negatively affects breastfeeding and infant care. for these reasons, it is imperative to provide adequate postoperative analgesia in this patient population

local wound infiltration is an attractive strategy since it is efficacious and side effects are minimal. nowadays, there is a trend toward preferring ropivacaine over other local anesthetic agents due to the longer duration of action and better safety profile. local anesthetic infiltration, however, has a limitation in that pain relief is offered till the effects of local anesthetic action lasts. efforts are being made to prolong the duration of action of local anesthetic skin infiltration, and dexmedetomidine is one such agent which can potentiate and prolong the duration of local anesthetic wound infiltration for pain relief. a transversus abdominis plane (tap) block provides analgesia of the anterior and lateral abdominal wall below the umbilicus by blocking the t6-l1 segmental nerves as they lie within the fascial plane between the transversus abdominis and internal oblique muscles: bilateral block for midline abdominal incision. it was first described in 2001 by rafi as a traditional blind landmark technique using the lumbar triangle of petit. local anesthetic is then injected between the internal oblique and transverse abdominis muscles just deep the fascial plane, the plane through which the sensory nerves pass

Eligibility criteria:
inclusion criteria: * pregnant women aged 20-35 years * gestational age between 37-40 weeks * pregnant women undergoing elective cesarean section * medically free * singleton pregnancy exclusion criteria: * emergency cesarean section * diabetic * hypertensive * severe anemia * multiple pregnancy * complication during section
a self-care mobile health app in individuals with heart failure

Conditions: Self-Management; Mobile Applications; Heart Failure

Summary: this study was designed to determine the potential benefits that individuals with heart failure (hf) could experience from using a mobile application.

the mobile application is called the heart failure health storylines (hfhs). the potential benefits will be examined by determining the changes in physical activity and quality of life of the participants, who will use the application and compare the results with the participants, who will not use the application.

Eligibility criteria:
inclusion criteria: * adults with chronic heart failure, class i - iii based on new york heart association (nyha) scale * walking independently with/without an assistive device exclusion criteria: the participant will be excluded if one or more of the following is present * cognitive impairment (\< 26 on montreal cognitive assessment). * uncorrected vision * hearing problems * neurological disorders. * cannot speak and read the english language, * not owning a smart cell phone with internet access.
porous and non-porous bone grafts in intra-bony periodontal defects

Conditions: Periodontal Disease

Summary: till date, no study has been reported in the literature where porous bioactive glass was used for the management of periodontal osseous defects. in this context, the present study is designed to assess the efficacy of the porous variant of bioactive glass and compare with that of nonporous variant using cone beam computed tomography.

objectives: 1. to evaluate clinically the periodontal healing with porous variant of bioactive glass placed in the intra bony defects at an interval of 6 months. 2. to evaluate clinically the periodontal healing with non porous variant of bioactive glass placed in the intra bony defects at an interval of 6 months. 3. to evaluate the radiographic changes in the intra bony defect grafted with porous variant of bioactive glass at baseline and an interval of 6 months. 4. to evaluate the radiographic changes in the intra bony defect grafted with non porous variant of bioactive glass at baseline and an interval of 6 months. 5. to compare clinically soft tissue healing for sites grafted with porous variant of bioactive glass and sites grafted with non porous variant of bioactive glass in the treatment of periodontal intra bony defects at an interval of 6 months. 6. to compare the radiographic changes for sites grafted with porous variant and sites grafted with non porous of bioactive glass in the treatment of periodontal intra bony defects at an interval of 6 months.

Eligibility criteria:
inclusion criteria: * inclusion criteria 1. age: 18-55 years. 2. probing depth \>5mm. exclusion criteria: * exclusion criteria 1. history of periodontal treatment last six months. 2. bleeding disorders. 3. gross oral pathology.
clinical impact of thoracic scanographic characteristics of hematologic malignancy patients

Conditions: Mediastinal Diseases

Summary: the mediastinum can be the site of benign or malignant tumors, including 10 to 20% of hematological malignancies. mediastinal mass syndrome (mms) includes symptoms due to irritation, invasion or compression of the organs of the mediastinum. this syndrome includes respiratory manifestations that may be secondary to compression of the tracheobronchial tree, venous vascular manifestations with the superior vena cava syndrome or arterial manifestations, cardiac manifestations, digestive or nervous manifestations. the management of a mediastinal syndrome is a diagnostic and therapeutic emergency requiring the collaboration of several disciplines in order to achieve the most effective but least deleterious way possible to diagnostic imaging, etiological biopsy, and the possible implementation of life-saving symptomatic measures before the initiation of etiological treatment. diagnostic thoracic imaging relies primarily on thoracic computed tomography (ct) to determine the size and nature of the mediastinal mass, the presence and extent of tracheobronchial or great vessel compression, the presence of pleural and/or pericardial effusion, pulmonary embolism, parenchymal lesions, and possibly subdiaphragmatic lesions. however, the potential severity of mms is often under-diagnosed in adult patients, particularly in the context of hematologic malignancy. indeed, we have very little literature on the initial management of these patients at risk. the present study propose to conduct the first multicenter study to analyze the characteristics (clinical, scanographic, echocardiographic, hematological and resuscitation) of the initial management of patients with symptomatic mms at diagnosis or at relapse of a patient with mh admitted to the intensive care unit (icu).


Eligibility criteria:
inclusion criteria: * hematologic malignancy at diagnosis or relapse * symptomatic mediastinal mass syndrome * admission to the icu, continuous medical surveillance (cms) or intensive care (ic) for symptomatology related to mms * chest ct (after maximum 48 hours of corticosteroid therapy (1mg/kg/ prednisone equivalent), maximum 15 days before and 5 days after admission to icu) * maximum administration of corticosteroid therapy 48 hours before admission to the icu (maximum 1mg/kg/ prednisone equivalent) * no prior pleural or pericardial drainage * study period: 01/01/2014 - 31/12/2021 (8 years) exclusion criteria: * no diagnosis of hematologic malignancy * diagnosis of solid benign or malignant tumor * no mediastinal mass syndrome * no admission to icu/cms * no chest ct scan meeting inclusion criteria * administration of corticosteroids for more than 48 hours prior to admission to the icu and/or prior to chest ct * lack of social security affiliation.

Keywords: mediastinal mass syndrome
prediction of kidney injury after hyperthermic intraperitoneal chemotherapy (hipec)* with machine learning

Conditions: Acute Kidney Injury; Chemotherapy

Summary: patients undergoing cytoreductive surgery with hyperthermic intraoperative chemotherapy (crs with hipec) are prone to postoperative kidney dysfunction. previous models predicting kidney injury after crs with hipec did not include intraoperative physiologic data. this study is designed to include not only mean arterial pressure but other parameters such as systolic, diastolic arterial pressure, heart rate, oxygen saturation, body temperature, cardiac index, stroke volume variation and many other physical parameters using a data collection system that can record them every 1-7 seconds. the data will be analyzed using machine learning algorithms.


Eligibility criteria:
inclusion criteria: * patients undergoing cytoreductive surgery with hyperthermic intraoperative chemotherapy exclusion criteria: * patients under 19
safety and efficacy of fibrinogen concentrate in aortic arch surgery involving moderate hypothermic circulatory arrest

Conditions: Proximal Aortic Dissection

Summary: bleeding is a common complication of cardiac surgery, especially aortic arch surgery involving moderate hypothermic circulatory arrest. fibrinogen concentrate is increasingly used to treat coagulopathic bleeding in cardiac surgery, although its effectiveness and safety are unknown. fibrinogen concentrate was administered to 54 patients when the fibrinogen level was below 1.5 g/l after protamine reversal. additionally, 30 patients were enrolled as the non-fc-treated group.

the aim of this prospective study was to investigate the safety and efficacy of fibrinogen concentrate in patients with acute type a aortic dissection. eighty-four acute type a aortic dissection patients undergoing emergency aortic arch surgery involving moderate hypothermic circulatory arrest were included. the clinical data, standard laboratory tests and plasma fibrinogen levels were obtained at 5 time points. the investigators analyzed the standard laboratory tests, the plasma fibrinogen levels, the volumes of cumulative postoperative drainage and transfused allogenic blood products in 84 patients. the primary and secondary end points were determined and considered.the primary endpoint (efficacy endpoint) included the volumes of individual allogeneic blood products, volumes of cumulative drainage within 24 h and 48 h and 5 days volumes after infusion of fibrinogen concentrate as well as the rates of reoperation due to bleeding. the secondary endpoint (safety endpoint) for the study was the incidence of serious adverse events from infusion of fibrinogen concentrate to day 45. the serious adverse events defined for the evaluation of safety of fibrinogen concentrate were death, pulmonary embolism and other thromboembolic or ischemic events (myocardial infarction, paraplegia and cerebral infarction).

Eligibility criteria:
inclusion criteria: * the participants aged 18 years or above who were undergoing emergency aortic arch surgery involving moderate hypothermic circulatory arrest for an acute type a aortic dissection exclusion criteria: * the participants with congenital or acquired coagulation disorders, previous surgery at the same site, death prior to planned surgery, stroke or myocardial infarction within 2 months before surgery and use of aspirin, clopidogrel or vitamin k antagonists within 2 to 5 days before surgery.

Keywords: blood loss coagulopathy fibrinogen concentrate transfusion
feasibility study of pneumrx's lung volume reduction coil (lvrc)

Conditions: Emphysema

Summary: this is a multicenter single arm open label study. the primary objective is to evaluate the safety and effectiveness of the lung volume reduction coil (lvrc) for the treatment of patients with emphysema in multiple centers.


Eligibility criteria:
inclusion criteria: * greater than or equal to 35 years of age * bilateral heterogenous emphysema * patient has stopped smoking for a minimum of 8 weeks * read, understood and signed the informed consent form exclusion criteria: * patient has a history of recurrent significant respirator infection * patient has an inability to walk \> 140 meters * patient has evidence of other disease that may compromise survival such as lung cancer, renal failure, etc * patient is pregnant or lactating * patient has clinical significant bronchiectasis * patient has had previous lvr surgery, lung transplant or lobectomy * patient has been involved in other pulmonary drug studies within 30 days prior to this study

Keywords: emphysema copd repneu
calerie (tufts) - comprehensive assessment of long-term effects of reducing intake of energy

Conditions: Aging

Summary: this study is one of three calerie trials that test the hypothesis that a reduced calorie, nutritionally sound diet increases the length of life and prevents some age-related chronic diseases such as cancer, diabetes, and cardiovascular disease. the three sites that are participating in the calerie trial represent a diversity of subject populations and interventional strategies.

researchers at the jean mayer usda human nutrition research center on aging at tufts university are enrolling overweight men and women aged 20-42 in a 1-year study to develop an effective calorie restricted regimen that minimizes hunger and prevents weight regain. the study also examines the effects of weight loss on body composition, metabolism and aging. two different diets containing usual foods and a healthy balance of nutrients will be tested at 2 levels of caloric restriction, 10% and 30% (in other words, 90% or 70% of what one would normally eat). weight loss is expected for most volunteers participating in this study, but cannot be guaranteed.

Eligibility criteria:
inclusion criteria * healthy men and women * body mass index (bmi) = 25-30 * slightly overweight, \< 275 lbs * women 25-45, pre-menopause * men 25-50 * not traveling often or planning to move exclusions: * cardiovascular disease or blood pressure greater than 160/90 * diabetes * major psychiatric disorders * eating disorders * post obese; previous bmi \> 32 * weight change of more than ten pounds in the past 90 days * over 275 pounds * smoking * regular exercise, more than twice per week * current prescription drug use, except oral contraceptives * alcoholism or substance abuse * pregnant or lactating (breast feeding), planning to become pregnant, or not regularly using contraception * abnormal electrocardiogram (ekg) * local resident for less than one year * occupations requiring full alertness and motor skills, with no allowance for a chance of postural dizziness (airline pilots, etc.) * injuries by any metallic object that is still present in the body * braces, non-removable dentures, or non-removable bridgework

Keywords: longevity calorie restriction physical activity weight loss